Nathan Denlinger
Overview
Explore the profile of Nathan Denlinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
222
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bajwa A, Zhao Q, Geer M, Lin C, Westholder J, Maakaron J, et al.
Blood Adv
. 2024 Oct;
9(1):170-175.
PMID: 39437770
Chimeric antigen receptor T-cell (CAR-T) therapies are effective in many hematologic malignancies; however, adverse events including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) can affect a...
2.
Steiner C, Denlinger N, Huang X, Yang Y
Front Immunol
. 2024 Aug;
15:1426418.
PMID: 39211052
Stem-like CD8 T cells (T) are a subset of immune cells with superior persistence and antitumor immunity. They are TCF1 PD-1 and important for the expansion of tumor specific CD8...
3.
Voorhees T, Bezerra E, Denlinger N, Jaglowski S, de Lima M
Clin Lymphoma Myeloma Leuk
. 2024 Apr;
24(10):649-652.
PMID: 38643029
Chimeric antigen receptor T-cell (CAR-T) therapy has significantly impacted treatment algorithms and clinical outcomes for a variety of patients with hematologic malignancies over the past decade. The field of cellular...
4.
Denlinger N, Song N, Zhang X, Jeon H, Peterson C, Wang Y, et al.
Blood Adv
. 2024 Apr;
8(12):3140-3153.
PMID: 38607381
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Robust biomarkers and a complete understanding of CAR T-cell function in the postinfusion phase remain...
5.
Chan W, Williams J, Sorathia K, Pray B, Abusaleh K, Bian Z, et al.
Exp Hematol Oncol
. 2023 Sep;
12(1):79.
PMID: 37740214
Background: Mantle cell lymphoma (MCL) is a rare B-cell non-Hodgkin lymphoma subtype which remains incurable despite multimodal approach including chemoimmunotherapy followed by stem cell transplant, targeted approaches such as the...
6.
Azar J, Evans J, Sikorski M, Chakravarthy K, McKenney S, Carmody I, et al.
JCI Insight
. 2023 Feb;
8(6).
PMID: 36749632
We assessed vaccine-induced antibody responses to the SARS-CoV-2 ancestral virus and Omicron variant before and after booster immunization in 57 patients with B cell malignancies. Over one-third of vaccinated patients...
7.
Zurko J, Nizamuddin I, Epperla N, David K, Cohen J, Moyo T, et al.
Blood Adv
. 2022 Sep;
7(12):2657-2669.
PMID: 36094847
Most patients receiving chimeric antigen receptor T-cell therapy (CAR-T) for aggressive B-cell non-Hodgkin lymphoma (B-NHL) do not experience a durable remission. Several novel agents are approved to treat relapsed, refractory...
8.
Peterson C, Denlinger N, Yang Y
Cancers (Basel)
. 2022 Aug;
14(16).
PMID: 36010965
Cancer immunotherapy has revolutionized the field of oncology in recent years. Harnessing the immune system to treat cancer has led to a large growth in the number of novel immunotherapeutic...
9.
Zurko J, Ramdial J, Shadman M, Ahmed S, Szabo A, Iovino L, et al.
Haematologica
. 2022 Jul;
108(1):98-109.
PMID: 35833303
Allogeneic hematopoietic cell transplantation (alloHCT) can potentially salvage large B-cell lymphoma (LBCL) patients experiencing treatment failure after chimeric antigen receptor T-cell therapy (CAR T). Nonetheless, data on the efficacy and...
10.
Murdock H, Kim H, Denlinger N, Vachhani P, Hambley B, Manning B, et al.
Blood
. 2022 Mar;
139(24):3546-3557.
PMID: 35286378
Older patients with acute myeloid leukemia (AML) have high relapse risk and poor survival after allogeneic hematopoietic cell transplantation (HCT). Younger patients may receive myeloablative conditioning to mitigate relapse risk...